Oxytocic Pharmaceuticals Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2029
Overview
Global Oxytocic Pharmaceuticals Market size was valued at US$ 3.52 Bn in 2022 and the total revenue is expected to grow at 4.3% through 2022 to 2029, reaching nearly US$ 4.73 Bn.
Global Oxytocic Pharmaceuticals Market Overview:
Oxytocics are a class of medicines used at the end of pregnancy, during labor, and after delivery to cause the smooth musculature of the uterus to contract selectively. Oxytocic medications are used in maternity for a variety of purposes, including induction of labor, labor arrest treatment, contraction stress testing, labor management, and the treatment of uterine atony and postpartum hemorrhage. In the event of a miscarriage, the medication is also used to terminate the fetus. Following a C-section, oxytocic medications are given to prevent uterine atony. Due to the lack of vasopressin, synthetic oxytocin derivatives might cause an antidiuretic effect.
To know about the Research Methodology :- Request Free Sample Report
The report has covered the market trends from 2018 to forecast the market through 2029. 2022 is considered a base year however 2022's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done good in lockdown also and specific strategic analysis of those companies is done in the report.
Global Oxytocic Pharmaceuticals Market Dynamics:
The key reason driving the growth of the oxytocic pharmaceuticals market is an increase in the trend of giving birth in hospitals rather than at home, as well as an increase in the number of caesarian procedures. Furthermore, the numerous types of goods offered by various firms related to oxytocic drugs in order to acquire market share are causing competition in the oxytocic pharmaceuticals industry. The primary issues limiting the growth of the oxytocic pharmaceutical industry are the negative effects associated with oxytocic medications that cause excessive bleeding following vaginal birth due to postpartum hemorrhage.
Over the projected period, sales of the market will be driven by improvements in newer oxytocic medicines through license agreements. Furthermore, increasing the use of Antepartum oxytocin injection to increase uterine contractions will have a good impact on oxytocic pharmaceutical demand. Manufacturers are focused on methods such as new Treatment Type innovations, alliances, and expansions to increase their Treatment Type range as competition is projected to rise in the future years.
Several oxytocic products are available from well-known companies. The most prominent brands contending for a greater portion of the worldwide oxytocic market include Pitocin, Oxytocin, Evatocin, Syntocinon, Pitocin, Duratocin, Cytotec, and Tiacinon. However, due to its widespread availability, the synthetic oxytocin derivatives category is expected to dominate the market. Similarly, hospitals are likely to become the market's most important end-use sector.
In addition, mergers and acquisitions are still popular tactics among market competitors. Tonix Pharmaceuticals, for example, signed a licensing agreement with Katana Pharmaceuticals in 2022 to expand the use of its intranasal potentiated oxytocin medication to treat metabolic illnesses like obesity, diabetes, and insulin resistance.
Global Oxytocic Pharmaceuticals Market Segment Analysis:
The Postpartum hemorrhage (PPH) segment is dominating the Treatment Type segment of the Global Oxytocic Pharmaceuticals Market:
Postpartum hemorrhage (PPH), a kind of obstetric hemorrhage, was the main cause of maternal mortality. Every year, 14 million cases of PPH are reported by the World Health Organization (WHO) for the treatment of PPH, oxytocin injection is indicated. 1-2mU/min is the recommended dose for oxytocic medicines. Hipofisina, Evatocin, Litocin, Pitogin, Piton-S, and Obcin Octocin are some of the major brands commercially marketed. Carbetocin, Misoprostol, and Syntocinon, among other oxytocic medicines, have yet to get FDA approval.
The Hospital segment is considered to supplement the growth of the Global Oxytocic Pharmaceuticals Market.
The hospital segment is likely to grab more attention in the end-use segment of the global oxytocic pharmaceuticals market with largest market share of 67% in 2022. Oxytocin is extensively used in perinatal medicine and can cause serious side effects on a high dose. Perinatal medicines are used in pregnant women during labor pain and lactating mothers. The injection of oxytocin, which is used to induce labor or intensify contractions, is normally given intravenously in a hospital under medical supervision. Oxytocic drugs are also used for several indications in obstetrics and obstetric anesthesia in hospitals. Synthetic oxytocin is a widely used drug as compare to natural oxytocin. Moreover, a high dose of synthetic oxytocin may lead to various side effects inpatient. However, oxytocin is widely prescribed in hospitals as compared to any other clinic. Moreover, the larger availability of drugs in hospital pharmacies is a key factor responsible for the growth of the market.
Global Oxytocic Pharmaceuticals Market Regional Insights:
North America is likely to boost the growth of the oxytocin Pharmaceuticals market.
North America is estimated to grow at a CAGR of 4.9% in the forecast period. Resulting in an increase in caesarian procedures, involvement in R&D, government initiatives, great advancement in the field of oxytocic functions, awareness regarding maternal care, and developed healthcare infrastructure, North America is expected to dominate the oxytocic pharmaceuticals market, followed by Europe and the Asia Pacific. further, Due to a growth in labour induction techniques in the region, post-partum bleeding has become the most appealing indication segment. Also, market competitors in the region are increasing their innovations in medication combinations and improving the pharmacological action of drug activities.
MEA is likely to support the growth of the oxytocic pharmaceuticals market in the forecast period.
Leading to a shortage of sufficient nutrition for pregnant women, the MEA region has the highest frequency of post-partum hemorrhage of all the regions. Due to a lack of healthcare infrastructure and understanding about pregnancy-related issues among African women, Africa's contribution to the prevalence of postpartum hemorrhage in the MEA area is on the higher end. In African countries, the prevalence of postpartum hemorrhage is as high as 25.7 %, while in Asian countries it is as low as 8.5 percent.
The objective of the report is to present a comprehensive analysis of the Global Oxytocic Pharmaceuticals Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Global Oxytocic Pharmaceuticals Market dynamics, structure by analyzing the market segments and project the Global Oxytocic Pharmaceuticals Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global Oxytocic Pharmaceuticals Market make the report investor’s guide.
Global Oxytocic Pharmaceuticals Market Scope: Inquire before buying
| Oxytocic Pharmaceuticals Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 3.52 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 4.3% | Market Size in 2029: | US $ 4.73 Bn. |
| Segments Covered: | by Treatment Type | Pre-eclampsia/Eclampsia Postpartum Hemorrhage Others |
|
| by End User | Hospitals Maternity Centre Clinics |
||
Global Oxytocic Pharmaceuticals Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Global Oxytocic Pharmaceuticals Market Key Player
1. App Pharmaceuticals LLC
2. Teva Parenteral Medicines Inc.
3. Abbott laboratories
4. JHP Pharmaceuticals LLC
5. Novartis Pharmaceuticals Corporation
6. LBS Labs,
7. Baxter Healthcare Corporation
8. Pfizer Inc
9. Fresenius Kabi
10.Biofutura
11.Ferring
12.Biofutura SpA
13.Dr. Reddy’s Laboratories
14.Granules Pharmaceuticals, Inc.,
FAQs:
1. What is the global Oxytocic Pharmaceuticals market value in 2022?
Ans: Global Oxytocic Pharmaceuticals market value in 2022 was estimated as 3.52 Billion USD.
2. What is the global Oxytocic Pharmaceuticals market growth?
Ans: The global Oxytocic Pharmaceuticals market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.73 Billion by the end of 2029.
3. Which End-User segment is expected to dominate the global Oxytocic Pharmaceuticals market during the forecast period?
Ans: The Hospital segment is projected to lead the market growth and held the largest market share of 67% in 2022, owing to increase in caesarian procedures and increasing birth rate.
4. Who are the key players in the Oxytocic Pharmaceuticals market?
Ans: Some key players operating in the Oxytocic Pharmaceuticals market include App Pharmaceuticals LLC, Teva Parenteral Medicines Inc., Abbott laboratories, JHP Pharmaceuticals LLC, and Novartis Pharmaceuticals Corporation.
5. What is the key driving factor for the growth of the global Oxytocic Pharmaceuticals market?
Ans: Key factors that are driving the Oxytocic Pharmaceuticals market growth include Highly fragmented market and increasing licensing activities are key trends observed in the market and Increasing labor induction procedures, growing prevalence of PPH, and prequalification from WHO will drive the sales of Oxytocic Pharmaceuticals.